US4637880A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Apparatus and method for therapeutic immunodepletion
Assignee: Cordis Corp
•
Filing: 1984-06-01
•
Granted: 1987-01-20
•
Expires: 2004-06-01
Abstract
Abstract A therapeutic apparatus for the removal of a harmful agent from blood is provided in the form of an array of hollow fiber bundles connected in parallel, wherein the interior surfaces of the individual hollow fibers are coated with a covalently bound proteinaceous or other immunoadsorbent selected for specific removal of the harmful agent. In the disclosed method the apparatus is optionally connected as an extracorporeal shunt between the artery and vein of a patient to be treated and the blood is alternately routed through one fiber bundle while the remaining fiber bundles undergo regeneration. Specific embodiments include the removal of rheumatoid factor by covalently bound immunoglobulin G and the removal of digoxin by covalently bound anti-digoxin.
Inventors
- 👤 Seymour P. Halbert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 06:20
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61M1/14; A61M1/16; A61M1/1621; A61M1/1633; A61M2205/00; A61M2205/75; A61M2205/7554; A61M2205/7581
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
374 words
Therapeutic extracorporeal shunt apparatus connectable to an artery and vein of a patient for removal of an agent from the patient's blood, said apparatus including provision for simultaneous treatment and on-line regeneration, comprising: (a) pick-up means for directing blood from an artery of the patient to the therapeutic extracorporeal shunt apparatus; (b) return means for directing blood to a vein of the patient from the therapeutic extracorporeal shunt apparatus; (c) a first blood flow path connecting said pick-up means and said return means and having closable ports for in-flow and out-flow of a regenerating fluid, comprising (i) a bundle of at least two hundred parallel hollow fibers having covalently bound to their inner surfaces an immunoadsorbent capable of binding said agent, thereby removing it from the patient's blood, and (ii) a header at each end of said bundle in fluid communication with the interior of the fibers in said bundle to provide a flow passage through the length of the interiors of said hollow fibers; (d) a second blood flow path, isolatable from said first blood flow path, connecting said pick-up means and said return means and having closable ports for in-flow and out-flow of a regenerating fluid, comprising (i) a bundle of at least two hundred parallel hollow fibers having covalently bound to their inner surfaces an immunoadsorbent capable of binding said agent, thereby removing it from the patient's blood, and (ii) a header at each end of said bundle in fluid communication with the interior of the fibers in said bundle to provide a flow passage through the length of the interiors of said hollow fibers; (e) first valve means for selectively flowing blood through said first blood flow path or said second blood flow path; and (f) second valve means for selectively flowing regenerating fluid through either said first blood flow path or said second blood flow path while blood is flowing through the other blood flow path, wherein said parallel hollow fibers are of a number and size selected to provide for an extracorporeal blood volume and flow rate sufficient, under the impetus of arterial pressure, to provide adequate flow through and contact with the hollow fibers of said first blood flow path for efficacious, continuous treatment of said patient.
Claim 2
Dependent Claim
374 words
Therapeutic extracorporeal shunt apparatus connectable to an artery and vein of a patient for removal of an agent from the patient's blood, said apparatus including provision for simultaneous treatment and on-line regeneration, comprising: (a) pick-up means for directing blood from an artery of the patient to the therapeutic extracorporeal shunt apparatus; (b) return means for directing blood to a vein of the patient from the therapeutic extracorporeal shunt apparatus; (c) a first blood flow path connecting said pick-up means and said return means and having closable ports for in-flow and out-flow of a regenerating fluid, comprising (i) a bundle of at least two hundred parallel hollow fibers having covalently bound to their inner surfaces an immunoadsorbent capable of binding said agent, thereby removing it from the patient's blood, and (ii) a header at each end of said bundle in fluid communication with the interior of the fibers in said bundle to provide a flow passage through the length of the interiors of said hollow fibers; (d) a second blood flow path, isolatable from said first blood flow path, connecting said pick-up means and said return means and having closable ports for in-flow and out-flow of a regenerating fluid, comprising (i) a bundle of at least two hundred parallel hollow fibers having covalently bound to their inner surfaces an immunoadsorbent capable of binding said agent, thereby removing it from the patient's blood, and (ii) a header at each end of said bundle in fluid communication with the interior of the fibers in said bundle to provide a flow passage through the length of the interiors of said hollow fibers; (e) first valve means for selectively flowing blood through said first blood flow path or said second blood flow path; and (f) second valve means for selectively flowing regenerating fluid through either said first blood flow path or said second blood flow path while blood is flowing through the other blood flow path, wherein said parallel hollow fibers are of a number and size selected to provide for an extracorporeal blood volume and flow rate sufficient, under the impetus of arterial pressure, to provide adequate flow through and contact with the hollow fibers of said first blood flow path for efficacious, continuous treatment of said patient.
Claim 3
Dependent Claim
12 words
The therapeutic apparatus of claim 1 wherein said immunoadsorbent is an immunoglobulin.
Claim 4
Dependent Claim
12 words
The therapeutic apparatus of claim 1 wherein said immunoadsorbent is an antigen.
Claim 5
Dependent Claim
199 words
A continuous process for the removal of an agent from the blood of a patient comprising: (a) diverting blood from an artery of the patient to an extracorporeal shunt; (b) passing, under the impetus of arterial pressure, the blood so diverted through the hollow interiors of 200-10,000 parallel hollow fibers comprising a first hollow fiber bundle, until a predetermined operating point is reached; (c) removing said agent from the blood as it passes through said hollow fibers by means of an immunoadsorbent covalently bonded to the inner surfaces of said hollow fibers; (d) returning the blood exiting said hollow fiber bundle to a vein of the patient; (e) upon reaching said predetermined operating point, switching the flow of diverted blood to said vein through the hollow interiors of 200-10,000 parallel hollow fibers comprising a second hollow fiber bundle; (f) isolating said first hollow fiber bundle from the diverted blood flow; (g) passing a regenerating solution through said first hollow fiber bundle to regenerate the immunoadsorbent; (h) sequentially passing a wash solution through said first hollow fiber bundle to prepare it for restoration to service; and (i) switching the flow of diverted blood back to said first hollow fiber bundle.
Claim 6
Dependent Claim
199 words
A continuous process for the removal of an agent from the blood of a patient comprising: (a) diverting blood from an artery of the patient to an extracorporeal shunt; (b) passing, under the impetus of arterial pressure, the blood so diverted through the hollow interiors of 200-10,000 parallel hollow fibers comprising a first hollow fiber bundle, until a predetermined operating point is reached; (c) removing said agent from the blood as it passes through said hollow fibers by means of an immunoadsorbent covalently bonded to the inner surfaces of said hollow fibers; (d) returning the blood exiting said hollow fiber bundle to a vein of the patient; (e) upon reaching said predetermined operating point, switching the flow of diverted blood to said vein through the hollow interiors of 200-10,000 parallel hollow fibers comprising a second hollow fiber bundle; (f) isolating said first hollow fiber bundle from the diverted blood flow; (g) passing a regenerating solution through said first hollow fiber bundle to regenerate the immunoadsorbent; (h) sequentially passing a wash solution through said first hollow fiber bundle to prepare it for restoration to service; and (i) switching the flow of diverted blood back to said first hollow fiber bundle.
Claim 7
Dependent Claim
13 words
A process in accordance with claim 4 wherein said immunoadsorbent is an immunoglobulin.
Claim 8
Dependent Claim
13 words
A process in accordance with claim 4 wherein said immunoadsorbent is an antigen.
Claim 9
Dependent Claim
16 words
A process in accordance with claim 4 wherein said regenerating solution is a low pH buffer.
References Cited (Backward Citations)
US3638794A
Cited
US4061141A
Cited
US4375414A
Cited
US4192748A
Cited
JPS5038141A
Cited
US4118314A
Cited
US4127481A
Cited
US4228013A
Cited
US4201673A
Cited
US4356267A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-01-19 | 1990-07-21 | 1991-01-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-01-19 | 1994-07-21 | 1995-01-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-01-19 | 1998-07-21 | 1999-01-20 | $7700.00 | Window Closed / Lapsed |